Shares are trading at $0.62 which is quite a bit higher than $0.52, the stock’s 50 day moving average and significantly higher than the 200 day moving average of $0.50. The 50 day moving average was up $0.10 and the 200 day average went up $0.12 or +23.91%. (NASDAQ:ATOS) shares saw heavy trading volume with 494K shares changing hands on Tuesday. Overall, volume was up 269.84% over the stocks normal daily volume.
Investors are a little more bearish on Atossa Genetics Inc. recently if you evaluate the uptick in short interest. The stock recorded a rise in short interest from September 15, 2017 to September 29, 2017 of 17.77%. Short shares grew from 1,002,202 to 1,180,304 over that period. The short-interest ratio increased to 1.0 and the percentage of shorted shares is 0.16% as of September 29.
Atossa Genetics Inc., launched on April 30, 2009, is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Business’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory. It holds the worldwide exclusive rights to develop and commercialize AfTG for the treatment and prevention of hyperplasia of the breast. The active pharmaceutical ingredient in AfTG is Afimoxifene (4-hydroxytamoxifen), which is an active metabolite of tamoxifen. Afimoxifene is an anti-estrogen with an affinity for estrogen receptor that is up to approximately 50 fold higher compared with that of tamoxifen. AfTG is a transdermal gel formulation of Afimoxifene. It is evaluating AfTG for use in several patient populations, including high risk women as determined by family history; women with breast hyperplasia, and women with a biopsy showing either atypical hyperplasia or DCIS. AfTG can be dispensed from a metered-dose container. A total of over 16 Phase I and Phase II studies have been conducted in various indications in the United States, United Kingdom, France, Poland and Czech Republic..